Xilio Therapeutics Announces Significant Pipeline Progress, Business Updates, and Robust Year-End 2025 Financial Results

Key Highlights and Strategic Developments

• Pipeline Advancement: Xilio Therapeutics is driving forward a suite of next-generation immuno-oncology (I-O) therapies, leveraging its clinically-validated masking technology. Notably, the company is:
  • Preparing for an IND (Investigational New Drug) submission for XTX501, a bispecific PD-1 / masked IL-2 agent, in mid-2026, with Phase 1 clinical trials anticipated in the second half of 2026 and initial data expected in the latter half of 2027.
  • Developing a first-in-class multi-specific, masked T cell engager
  • Progressing a masked T cell engager targeting CLDN18.2, with new preclinical data to be presented at the AACR Annual Meeting (April 2026; abstract #1619). CLDN18.2 is expressed in gastrointestinal and lung cancers.
  • Continuing evaluation of efarindodekin alfa (masked IL-12), with ongoing Phase 2 trials and option data package delivery to Gilead Sciences anticipated in the first half of 2027.
• Financial Strength:
  • Cash and cash equivalents surged to \$137.5 million as of December 31, 2025, up from \$55.3 million a year prior.
  • Xilio extended its cash runway through the end of 2027, excluding potential future milestone payments and the receipt of up to \$36.2 million in additional gross proceeds if all Series C warrants are exercised in the second half of 2026.
  • Collaboration and license revenue reached \$43.8 million for 2025 (up from \$6.3 million in 2024), driven by milestone payments from partnerships with AbbVie and Gilead, notably a \$17.5 million milestone achieved in Q3 2025.
  • R&D expenses increased to \$56.0 million in 2025, reflecting expanded manufacturing, preclinical, and clinical activities for XTX501, efarindodekin alfa, and masked T cell engager programs.
  • Net loss for 2025 improved to \$35.0 million (from \$58.2 million in 2024), primarily due to higher collaboration and license revenues.
  • Q4 2025 saw net income of \$10.4 million (vs. net loss of \$13.1 million in Q4 2024), indicating strong quarterly performance.
• Corporate Updates:
  • Sara Bonstein appointed Chair of the Board of Directors in January 2026.
  • \$35.8 million in gross proceeds raised via Series B warrant exercises in Q4 2025; a further \$40.0 million raised through prefunded warrants in February 2026.
  • Milestone achievement under Xilio’s collaboration with AbbVie for masked antibody-based immunotherapy program.
  • Strategic partnerships and funding led by prominent investors (Coastlands Capital, OrbiMed, Perceptive Advisors, Gilead).

Pipeline Details & Potential Share Price Catalysts

• XTX501 – Bispecific PD-1 / Masked IL-2: Designed to selectively stimulate PD-1 positive, antigen-experienced T cells and overcome tolerability and clearance issues seen in non-masked IL-2 agents. Preclinical data shows robust monotherapy activity, even in PD-1 insensitive settings, and tumor-selective pharmacodynamics. Xilio positions XTX501 as a “backbone” for combination therapy in solid tumors, initially targeting metastatic non-small cell lung cancer.
• Masked T Cell Engager Programs:
  • CLDN18.2 (ATACR/SEECR formats): Modular architecture allows for masking and co-stimulatory enhancements. CLDN18.2 is prevalent in gastrointestinal and lung cancers. Preclinical data to be presented at AACR, potentially driving investor interest.
  • PSMA & STEAP1 (SEECR format): These antigens are the most prevalent in prostate cancer. Dual targeting aims to minimize resistance due to antigen escape and address tumor heterogeneity. Development candidate nomination expected Q2 2026; IND-enabling studies to follow.
• Efarindodekin Alfa (Masked IL-12): Ongoing Phase 2 trial with option package delivery to Gilead in H1 2027 could trigger further milestone payments and partnership expansion.

Financial Performance & Outlook

• Cash Position: \$137.5 million at year-end 2025, with substantial additional capital raised in early 2026. Cash runway extends through 2027, supporting ongoing clinical programs and new IND submissions.
• Revenue Growth: Collaboration and license revenue increased sevenfold year-over-year, reflecting successful execution of partnership milestones with AbbVie and Gilead.
• Expense Management: Increased R&D and G&A expenses stem from expanded pipeline activities and professional fees, partially offset by reduced insurance costs.
• Net Loss Reduction: Improved bottom-line performance driven by revenue growth and partnership milestones.

Shareholder Impact & Price Sensitivity

• The announcement of new clinical programs, particularly the potential first-in-class masked T cell engagers and the best-in-class potential of XTX501, could significantly enhance Xilio’s market position and investor confidence.
• Milestone payments and collaboration revenue from AbbVie and Gilead, along with substantial capital raises, bolster Xilio’s financial stability and fund future growth, potentially impacting share value.
• Upcoming clinical data releases and pipeline milestones (IND submissions, candidate nominations, and preclinical data presentations) are likely to be price-sensitive events.
• The extension of the cash runway through 2027 reduces dilution and financial risk, which is positive for shareholders.
• The possibility of up to \$36.2 million in additional proceeds from Series C warrants in the second half of 2026 represents a further cash infusion opportunity.

Management’s Forward-Looking Statements

Xilio emphasized the promise of its masking technology and multi-specific I-O therapies, but cautioned that forward-looking statements are subject to risks including clinical development timelines, regulatory challenges, supply chain, intellectual property, funding needs, geopolitical uncertainties, and partnership sustainability.

Condensed Financial Data

Conclusion

Xilio Therapeutics’ 2025 year-end report showcases substantial progress in its immuno-oncology pipeline, solid financial gains, strategic capital raises, and milestone achievements with key partners. With major clinical milestones and data disclosures on the horizon, the company is well-positioned for potential share price appreciation, contingent on execution and successful clinical outcomes.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties, including those outlined in Xilio’s SEC filings. Investors should conduct their own due diligence and consult financial advisors before making investment decisions.

View Xilio Therapeutics, Inc. Historical chart here